Idarubicin in advanced breast cancer: A phase II study

R. Lionetto; P. Pronzato; P. F. Conte; M. R. Sertoli; D. Amoroso; R. Rosso

Idarubicin in advanced breast cancer: A phase II study

R. Lionetto, P. Pronzato, P. F. Conte, M. R. Sertoli, D. Amoroso, R. Rosso

Research output: Contribution to journal › Article › peer-review

Abstract

Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m² x 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of the new anthracycline antibiotic.

Original language	English
Pages (from-to)	1439-1440
Number of pages	2
Journal	Cancer Treatment Reports
Volume	70
Issue number	12
Publication status	Published - 1986

ASJC Scopus subject areas

Cancer Research
Oncology

Fingerprint Dive into the research topics of 'Idarubicin in advanced breast cancer: A phase II study'. Together they form a unique fingerprint.

Cite this

@article{542c9370465e48f1bc49a50339932393,

title = "Idarubicin in advanced breast cancer: A phase II study",

abstract = "Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 x 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of the new anthracycline antibiotic.",

author = "R. Lionetto and P. Pronzato and Conte, {P. F.} and Sertoli, {M. R.} and D. Amoroso and R. Rosso",

year = "1986",

language = "English",

volume = "70",

pages = "1439--1440",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "U.S. National Cancer Institute",

number = "12",

}

TY - JOUR

T1 - Idarubicin in advanced breast cancer

T2 - A phase II study

AU - Lionetto, R.

AU - Pronzato, P.

AU - Conte, P. F.

AU - Sertoli, M. R.

AU - Amoroso, D.

AU - Rosso, R.

PY - 1986

Y1 - 1986

N2 - Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 x 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of the new anthracycline antibiotic.

AB - Twenty-nine patients with metastatic breast cancer were treated orally with idarubicin (15 mg/m2 x 3 days every 3-4 weeks). Objective response was seen in 31% of all patients. Toxicity was acceptable. There should be further clinical trials of the new anthracycline antibiotic.

UR - http://www.scopus.com/inward/record.url?scp=0022919699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022919699&partnerID=8YFLogxK

M3 - Article

C2 - 3466694

AN - SCOPUS:0022919699

VL - 70

SP - 1439

EP - 1440

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 12

ER -

Idarubicin in advanced breast cancer: A phase II study

Abstract

ASJC Scopus subject areas

Other files and links

Cite this